Regulation & law · 29/11/2017

National Heart, Lung, and Blood Institute to Consider Exclusive Patent License for Renal Cell Carcinoma Treatment

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to T-Cure Bioscience, Inc. to commercialize a potential treatment for renal cell carcinoma using transduced T-cells with HLA A11 restricted CT-RCC HERV-E reactive T-cell receptors.